Investment Opportunity

Breakthrough Discoveries That Could Revolutionize Anti-Inflammatory Medicine

Juva Life Inc | Listed on: CSE:JUVA  |  OTCQB:JUVAF | JUVA.CN | JUVAF

Having already established itself as a successful cannabis company, two recent discoveries are allowing Juva Life Inc. to make a long-planned expansion into pharmaceuticals. It may only be a matter of time before Big Pharma comes in and the company’s valuation goes from the millions to the billions.

Why You Should Consider Investing

  • 1. New discoveries solve industry blind spot

    Juva Life’s discovery of two new cannabis molecules could revolutionize the enormous market for anti-inflammatory products.

  • 2. Highly efficient product development pathway

    Juva Life’s accelerated and innovative approach to drug development incurs a fraction of the cost, time, and risk of traditional clinical pathways.

  • 3. Team behind the company are trailblazers

    Juva Life’s company operations are led by a team of cannabis visionaries, both on the business and scientific sides of the sector.

  • 4. Commercial success already helps to fund next stage

    Juva Life’s product R&D is funded by a vertically integrated retail cannabis model.

  • 5. Discoveries are extremely attractive to Big Pharma

    Juva Life is targeting major pharma takeout or key licensing agreements over the medium term that could mean the outfit is significantly undervalued at the moment.

  • 6. News of breakthrough yet to become widely known

    Perfect time to invest as the wider market is yet to catch on to the significance of Juva Life’s anti-inflammatory discoveries.

When considered together, the case here is extremely compelling and smart investors will be quick to see the potential. Access our full report to discover just how big the opportunity really is.

Find out more

What You Need to Know: Revolutionary New Discoveries

.

Many don’t realise, but inflammation is a key cause of many of the world’s most life-threatening illnesses.

From heart disease to diabetes, kidney problems to many forms of cancer, the issues are often caused by the immune system response.

Of course, we currently have various drugs that aim to reduce inflammation, many of which are available over the counter like Tylenol and paracetamol.

Trouble is, these drugs are usually rather weak and ineffective. Worse still, they have quite a high level of toxicity, which means over reliance on them can cause other problems. It’s why you’ll no doubt have been told in the past not to take too many.

Still, even though many of the drugs available are not as effective as they could be, the anti-inflammatory market is set to be worth a massive $117 billion by 2027.

This is why Juva Life’s recent discoveries could be such game-changers. Not just for the valuation of the company itself, but for anti-inflammation treatment generally.

You see, the R&D team at Juva Life has uncovered what amounts to two entirely new molecules found in the cannabis plant that are proven to have extremely effective anti-inflammatory properties.

What’s particularly exciting here—especially for potential investors thinking about how widely this could be applied—is that both are derived from natural compounds and neither are terpenes or cannabinoids themselves despite being found in MJ.

Excitingly, this could mean they are both less toxic than alternatives and less exposed to the normal regulatory barriers faced by MJ products.

The implications here are huge and, as you would expect, Juva Life is already in the process of patenting its discoveries while at the same time optimizing them to uncover their full commercial potential.

Access our special report today to see for yourself just how significant Juva Life’s discoveries are and what they could mean for the company’s valuation moving forward.

.

What You Need to Know: Everything That’s Needed to Succeed

.

When a company makes a significant scientific breakthrough like Juva Life has here, you often find that they are ill-equipped to deal with it.

For a start, most experimental research and development in the MJ space is being done by very small start-ups, who—when faced with a potential breakthrough—would need to source significant financing to go any further.

That’s not the case with Juva Life.

For several years the company has been building up its commercial arm, developing a fully integrated model that includes serious cultivation sites in California and effective distribution channels around the US. This all helps to fund the more medicinal side of the business.

And it should be noted it’s no accident that it’s happened like this.

From the start, Doug Chloupek, founder and CEO of Juva Life, always intended to expand beyond the more commercial side of cannabis alone and into the broader, more therapeutic side of things. Indeed, his aim is for the company to embrace life sciences more generally.

Of course, with the breakthroughs the company has made, this move could be much easier than even Chloupek could have planned.

With strong financials behind and the inevitable interest of Big Pharma to come (as more and more is learned about its new molecules), whether it’s bought out, or becomes a licenser, Juva Life looks like it has a bright future. 

Indeed, the company's attractiveness to Big Pharma outfits leaves it looking undervalued at the moment.

Smart investors will be quick to see the huge potential here and be excited to realize they have an opportunity to get on board while news of Juva Life’s breakthroughs remains relatively under the radar.

Get the full details of what’s going on and what could happen over the coming weeks and months by accessing our special report. It’s free to download and read today.

.

Company Info

Founded by pioneers in the science and business of cannabis and guided by a team of highly-acclaimed medical professionals, Juva Life brings unprecedented depth of knowledge in the science and medicinal effects of cannabis.

Exchange / Symbol
CSE:JUVA
Market Capitalization
$ (usd)
Current price
$ (usd)
Current mid price
$ (usd)
52 Week high price
$ (usd)
52 Week low price
$ (usd)

Company Info

Founded by pioneers in the science and business of cannabis and guided by a team of highly-acclaimed medical professionals, Juva Life brings unprecedented depth of knowledge in the science and medicinal effects of cannabis.

Exchange / Symbol
OTCQB:JUVAF
Market Capitalization
$ (usd)
Current price
$ (usd)
Current mid price
$ (usd)
52 Week high price
$ (usd)
52 Week low price
$ (usd)

DOWNLOAD OUR SPECIAL REPORT to learn more about how Juva Life’s discoveries could revolutionize the global market for anti-inflammatory products.

IMPORTANT NOTICE AND DISCLAIMER

PAID ADVERTISEMENT

This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Juva Life JL002 to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of two hundred and sixteen thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.

CHANGES IN SHARE TRADING AND PRICE

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.

NO OFFER TO SELL OR BUY SECURITIES

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.

INFORMATION

Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.

NO FINANCIAL ADVICE

The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.

FORWARD LOOKING STATEMENTS

This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.

INDEMNIFICATION/RELEASE OF LIABILITY

By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.

TERMS OF USE AND DISCLAIMER

By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications.

INTELLECTUAL PROPERTY

All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.

AUTHORS: VALUETHEMARKETS

valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.